Author: Editor

Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Copanlisib Program. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

CRISTIANE DECAT BERGEROT, PhD PSYCHOLOGIST, POSTDOCTORAL FELLOW CITY OF HOPE COMPREHENSIVE CANCER CENTER discusses THE IMPACT OF THE PSYCHOSOCIAL MILIEU ON QUALITY OF LIFE AND SURVIVAL At the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Eric A. Singer, MD, MA, MS, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Section of Urologic Oncology Rutgers Cancer Institute of New Jersey Director, Distinction in Bioethics Program Rutgers Robert Wood Johnson Medical School discusses Ethical Issues in Kidney Cancer ?Research and Treatment at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Bellinda King-Kallimanis, PhD of U.S. Food and Drug Administration, Maryland (FDA ) discusses Incorporating Relevant and Meaningful ?Patient-Reported Outcomes in ?RCC Clinical Trials? at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

André P. Fay, MD, PhD Professor, PUCRS School of Medicine Chief, Medical Oncology Department – Hospital São Lucas da PUCRS/ Oncoclínicas Porto Alegre Visiting Scientist at Dana-Farber Cancer Institute/ Harvard Medical School discusses Patient And Physician Perspective at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Samra Turajlic BA, MBBS, MRCP, PhD, Consultant Medical Oncologist, Royal Marsden NHS Foundation Trust, London Cancer Research UK Clinician Scientist, Francis Crick Institute, London discusses Tracking Renal Cancer Evolution Through Space And Time at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

E. Jason Abel MD, FACS University of Wisconsin discusses Cytoreductive nephrectomy Placing recent clinical trials in context at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL

Dr. Jack West discusses the trial design of the PACIFIC trial of consolidation durvalumab (Imfinzi) after chemo/radiation for unresectable stage III NSCLC and highlights new data on overall survival and the different results in patient subgroups.

Earn CME: https://naccme.com/program/7309 In this Key Insights activity, Drs. Morton Coleman and John P. Leonard discuss highlights in lymphoma from Lymphoma & Myeloma 2018: An International Congress on Hematologic Malignancies. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7308 In this Key Insights activity, Drs. Morton Coleman and Richard R. Furman discuss CLL-related highlights from Lymphoma & Myeloma 2018: An International Congress on Hematologic Malignancies. © 2018 Imedex, an HMP Company

Earn CME: https://naccme.com/program/7307 In this Key Insights activity, Drs. Morton Coleman and Ruben Niesvizky discuss myeloma presentation highlights from Lymphoma & Myeloma 2018: An International Congress on Hematologic Malignancies. © 2018 Imedex, an HMP Company

Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Drs. Langer, Aggarwal, Bazhenova, and Ross examine a series of NSCLC cases. © 2018 Imedex, an HMP Company

Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Lyudmila Bazhenova discusses EGFR resistance in the era of osimertinib. © 2018 Imedex, an HMP Company

Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Charu Aggarwal discusses frontline options for targeted therapy with EGFR TKIs. © 2018 Imedex, an HMP Company

Earn CME Credit: https://naccme.com/program/7306 In this presentation from the 23rd Annual Perspectives in Thoracic Oncology, Dr. Helen Ross discusses the heterogeneity of NSCLC and precipitating oncogenic driver mutations. © 2018 Imedex, an HMP Company

Michael A.S. Jewett DEPARTMENT OF SURGICAL ONCOLOGY PRINCESS MARGARET CANCER CENTRE DIVISION OF UROLOGY THE UNIVERSITY OF TORONTO discusses Heterogeneity of Renal Cell Carcinoma: Lessons learned from biopsy and active surveillance of small renal masses (SRM) at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Kimberly Allman, MSN, CNP Cleveland Clinic Taussig Cancer Institute discusses Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic Renal Cell Carcinoma at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Ritesh Kotecha discusses Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Neeraj Agarwal Huntsman Cancer Center discusses Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab:?Results of the dose-escalation stage in ?patients with treatment-naïve advanced ?renal cell carcinoma at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Andrey Soares Medical Oncologist Centro Paulista de Oncologia and Hospital Israelita Albert Einstein SPChair LACOG GU gives an UPDATES LATIN AMERICAN COOPERATIVE ONCOLOGY GROUP (LACOG) at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Rodolfo Borges dos Reis, MD, PhD Uro-oncology Ribeirao Preto Medical School discusses LARCG Latin American Renal Cancer Group at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Alberto Diaz de Leon M.D. discusses Whole Body MRI for Detection of Renal Cell Carcinoma Osseous Metastases at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Abhishek A. Chakraborty Instructor in Medicine Department of Medical Oncology Laboratory of William Kaelin Dana-Farber Cancer Institute Harvard Medical School discusses Targeting Vulnerabilities Arising from Dysregulated Histone Demethylase Function in Kidney Cancer at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess Medical Center Research Fellow, Dana Farber Cancer Institute discusses A Secreted PD-L1 Splice Variant that Covalently Dimerizes and Mediates Immunosuppression at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

A Ari Hakimi MD Assistant Member, Department of Surgery, Urology Service Member, Immunogenomics and Precision Oncology Platform discusses the Novel metabolic insights into RCC biology and immune response at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Toni K. Choueiri, MD Director, Lank Center for Genitourinary Oncology Department of Medical Oncology Dana-Farber Cancer Institute discusses Neovax: From Translation to Bedside From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Thai H. Ho, MD, PhD Mayo Clinic Arizona discusses Targeting Epigenetics and Chromatin Remodeling Genes From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Thomas Powles Director of Barts Cancer Centre discusses The next therapeutic targets: TGFbeta From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Abhishek Tripathi MD Assistant Professor of Medicine University of Oklahoma Stephenson Cancer Center discusses Adenosine Pathway Inhibitors From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Ranjit S. Bindra, M.D., Ph.D. Associate Professor Departments of Therapeutic Radiology and Experimental Pathology Yale Cancer Center discusses Exploiting oncometabolite-induced DNA repair defects From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses whether the results improve outcomes enough to change our standard of care in this setting.         IMpower133, atezolizumab,  first line chemo, extensive stage SCLC

Suzanne Cole, MD FACP Medical Director, Community Cancer Clinic Richardson Plano UT Southwestern Medical Center discusses Engaging Clinical Trialists in the Community Setting From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Robert G. Uzzo, M.D. Willing G. Pepper Chairman of Surgery Fox Chase Cancer Center Temple University School of Medicine Chair, Department of Urology Urological Institute at Einstein Healthcare Network Philadelphia, PA USA discusses Creating Synergy in RCC: Collaborative Approaches to Value From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Hyung L. Kim, M.D. Director, Academic Urology Programs Cedars Sinai Medical Center discusses What is the Next Cytoreductive Surgical Trial? From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology MD Anderson Cancer Center discusses Combination Checkpoint Blockade with Surgery From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Phillip M. Pierorazio, MD Associate Professor of Urology and Oncology Brady Urological Institute, Department of Urology? Johns Hopkins Medicine, Baltimore, Maryland discusses Neoadjuvant PD1 Blockade to Prime the Immune System From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Dr. Andrew W. Silagy Urologic Oncology Research Fellow Memorial Sloan Kettering Cancer Center discusses An Evaluation of the Role of Cytoreductive Nephrectomy in Patients with Sarcomatoid RCC From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Nizar M. Tannir University of Texas MD Anderson Cancer Center, Houston, TX, USA discusses CheckMate 214 Retrospective Analyses From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Nieves Martinez Chanza Department of Oncology, Jules-Bordet Institute, Free University of Brussels (Belgium) discusses Safety and efficacy of checkpoint inhibitors From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Tian Zhang, MD Assistant Professor of Medicine Duke Cancer Institute discusses PDIGREE From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Thomas Powles Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, Royal Free NHS Trust, London, UK discusses Treatment-Free Survival Following Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Rana R. McKay, MD Assistant Professor of Medicine UC San Diego discusses Rationally Targeting the Bone with Radium Plus Cabozantinib From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Matt Campbell MD Assistant Professor GU Medical Oncology UT MD Anderson Cancer Center discusses Ongoing Clinical Trial Update: A Pilot Study of Pre-surgical Tremelimumab with or without Tissue Cryoablation From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Moshe C. Ornstein MD MA, Laura S. Wood RN MSN OCN, Kimberly Allman MSN CNP, Allison Martin PA-C Timothy Gilligan MD, Jorge A. Garcia MD, Brian I. Rini MD Cleveland Clinic Taussig Cancer Institute discusses Phase II trial of intermittent nivolumab From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Hans Hammers MD, PhD Associate Professor of Internal Medicine in the Division of Hematology-Oncology at UT Southwestern Medical Center discusses Tayloring Therapy: Therapy Intensification and Discontinuation From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Charles G. Drake MD / PhD Director GU Medical Oncology Co-Director: Immunotherapy Program Associate Director for Clinical Research Professor of Oncology and Urology Herbert Irving Cancer Center at Columbia University discusses Beyond Checkpoint ?Blockade From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Primo N Lara, Jr., MD Director, University of California Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean for Cancer Programs UC Davis School of Medicine, Sacramento, CA discusses Metastatic Renal Cell Cancer: Who Deserves Monotherapy? From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Michael B. Atkins, M.D. William M. Scholl Professor and Vice Chair Department of Oncology Deputy Director Georgetown-Lombardi Comprehensive Cancer Center discusses RCC: Putting Frontline Combination Data into Perspective From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Ewelina Morawa, MD Executive Medical Director CRISPR Therapeutics discusses Allogeneic Anti-CD70 CAR T Cells ?for Renal Cell Carcinoma From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Steven L. Chang, MD, MS Assistant Professor of Surgery, Harvard Medical School Surgical Oncologist, Dana-Farber Cancer Institute Associate Surgeon, Division of Urology, Brigham and Womens Hospital discusses Laparoscopic Vs Robotic Radical Nephrectomy: What are the Costs and Benefits? From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Alexander Kutikov, MD, FACS Professor and Chief, Urologic Oncology Fox Chase Cancer Center, Philadelphia, PA discusses Enucleation of Renal Mass: Why Would You Not Keep Your Distance? From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Gopal N. Gupta, MD, FACS Associate Professor Departments of Urology, Surgery and Radiology Cardinal Bernardin Cancer Center Loyola University Health System discusses Pro vs Con for Enucleation From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Steven S. Raman, MD FSAR FSIR Professor of Radiology, Urology and Surgery Division of Abdominal Imaging & Intervention Departments of Radiology and Urology David Geffen School of Medicine at UCLA discusses The Radiological Biopsy: Are we there yet? Imaging based renal mass diagnosis. From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

John Leppert, MD MS Associate Professor Stanford University Director of Urologic Oncology, VA Palo Alto discusses Overdiagnosis and the Harms of Overtreatment of Renal Cell Carcinoma From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Timothy McClure, MD Assistant Professor of Urology Assistant Professor of Interventional Radiology Weill Cornell Medicine discusses Emerging Ablative Technologies – Whats New And Is It Better? from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Jaime Landman Professor of Urology and Radiology Chairman, Department of Urology UCI discusses Renal mass biopsy in 2018: When, where and how? From the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

David Braun, MD, PhD, Dana-Farber Cancer Institute discusses Single Cell RNA-Sequencing in RCC from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Dr. Lisa Derosa, MD PhD Candidate Immunoncology – Pr. L. Zitvogel discusses The impact of the stool microbiome in RCC from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

James Brugarolas, M.D., Ph.D. Director, Kidney Cancer Program Principal Investigator, UT Southwestern Kidney Cancer SPORE Sherry Wigley Crow Endowed Chair in Cancer Research Professor of Internal Medicine/Hematology-Oncology Cancer Biology, Genetics, Development and Disease University of Texas Southwestern Medical Center discusses An Empirical Approach to Dissect the TME in RCC from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

James J. Hsieh MD PhD Professor, Molecular Oncology, Siteman Cancer Center, Washington University in St. Louis discusses RCC Profiling from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Neeraj Agarwal, MD Professor of Medicine Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research Co-Leader, HCI Experimental Therapeutics Program (CCSG Program) Director, GU Medical Oncology Huntsman Cancer Institute, University of Utah (NCI-CCC) Salt Lake City, UT Discusses Cell-free DNA (cfDNA) from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University discusses Cost-Effective Biomarkers Ready at our fingertips? from the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.

Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Bayer Larotrectinib Program. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Do-Youn Oh, M.D., of Seoul National University Hospital discusses Treating Advanced Biliary Cancer: M7824 Data. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Do-Youn Oh, M.D., of Seoul National University Hospital discusses Pembrolizumab Monotherapy In Biliary Cancer. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Do-Youn Oh, M.D., of Seoul National University Hospital discusses Future Of Biliary Cancer Treatment. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Do-Youn Oh, M.D., of Seoul National University Hospital discusses Future Of Biliary Cancer Treatment. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Sanjay Popat, M.D., of The Royal Marsden Hospital Discusses ALTA-1L Trial CNS Efficacy. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Tagawa, M.D., of Weill Cornell Medicine discusses PSMA-617 Study. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Tagawa, M.D., Of Weill Cornell Medicine discusses Availability Of PSMA-617 Radionuclide Therapy. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Fields, M.D., SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Whats on The Horizon For Bayer Pharmaceuticals. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

David Peereboom, M.D., Cleveland Clinic Discusses The Future Of Treating Glioblastoma. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Dra. Cristina Gutierrez talks about selecting the best doctor and communicating with the physician in treating prostate cancer

SpaceOAR gel and other preventive protocols to minimize side effects for radiation therapy for prostate cancer as detailed by Dra. Cristina Gutierrez

The benefits of hormonal therapy in conjunction with radiation treatment as discussed by Dra. Cristina Gutierrez

Dr. Cristina Gutierrez discusses treatment option decisions for prostate cancer

Pascal Besman Chief Operating Officer at PharmaMar discusses Emerging New Agents In SCLC. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Hope Rugo, M.D., University Of California San Francisco discusses EMBRACA Trial, Sensoring Process, QOL. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Hope Rugo, M.D., University Of California San Francisco discusses Talazoparib First Line Treatment. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Hope Rugo, M.D., University Of California San Francisco discusses IMpassion130, Solar-1 Trial Data. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Hope Rugo, M.D., University Of California San Francisco discusses EMBRACA Trial, FDA Approval Of Talazoparib. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Hope Rugo, M.D., University Of California San Francisco discusses Data On Neoadjuvant Talazoparib. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON3 Randomized Study. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON2 Trial, Rucaparib PARP Inhibitor Data. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON2 Trial Results. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

David Peereboom, M.D., Cleveland Clinic Discusses SL-701 Availability. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

David Peereboom, M.D., Cleveland Clinic Discusses New Plans With SL-701 Drug. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

David Peereboom, M.D., Cleveland Clinic Discusses How SL-701 Was Generated. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Pascal Besman Chief Operating Officer at PharmaMar discusses Whats On Deck For Lurbinectedin. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Pascal Besman Chief Operating Officer at PharmaMar discusses Upcoming SCLC Data. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Pascal Besman Chief Operating Officer at PharmaMar discusses Progress In SCLC Vs. NSCLC. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Pascal Besman Chief Operating Officer at PharmaMar discusses Lurbinectedin Data Presented This Year. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Pascal Besman Chief Operating Officer at PharmaMar discusses IO Likely In 1st Line SCLC. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Pascal Besman Chief Operating Officer at PharmaMar discusses Current Standard Of Care In SCLC. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Byoung Chul Cho, M.D., Yonsei Cancer Center discusses Efficacy & Safety Of M7824. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Byoung Chul Cho, M.D., Yonsei Cancer Center discusses NSCLC With M7824 Second Line Therapy. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Byoung Chul Cho, M.D., Yonsei Cancer Center discusses What To Expect In NSCLC & HN Cancer For 2019. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Michael Davidson, M.D., Royal Marsden Hospital, discusses Gastric & Esophageal Cancer: Treating Female Patients. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Michael Davidson, M.D., Royal Marsden Hospital, discusses Gender Differences: Gastric & Esophageal Cancer Treatment. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Fields, SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Larotrectinib, Xofigo, Copanlisib, & Regorafenib Research. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Scott Fields, SVP Head Pharmaceutical Development Oncology at Bayer Pharmaceuticals discusses Treatment With Xofigo, Abiraterone, & Copanlisib. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Thomas Helleday, Phd, Helleday Laboratory, Discusses Using Mutational Signatures To Tailor New Treatments. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit from high dose chest radiation therapy vs. standard dose therapy.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.

David Peereboom, MD, Cleveland Clinic Discusses SL-701 Phase Two Trial Study Results. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.

Diana Roettger, PhD, Head of Scientific and Medical Affairs and Imaging Clinical Research Expert at IAG Discusses Radiological Phenotyping For Glioma Study Outcomes. At ESMO Oncology Conference – Munich, Germany On October 19, 2018. www.ia-grp.com

Diana Roettger, PhD, Head of Scientific and Medical Affairs and Imaging Clinical Research Expert at IAG Discusses Next Steps In Image Analysis Research. At ESMO Oncology Conference – Munich, Germany On October 19, 2018. www.ia-grp.com

Diana Roettger, PhD, Head of Scientific and Medical Affairs and Imaging Clinical Research Expert at IAG Discusses Machine Learning & AI Contributions To Research. At ESMO Oncology Conference – Munich, Germany On October 19, 2018. www.ia-grp.com

Diana Roettger, PhD, Head of Scientific and Medical Affairs and Imaging Clinical Research Expert at IAG Discusses Advanced Imaging & AI In Clinical Trials. At ESMO Oncology Conference – Munich, Germany On October 19, 2018. www.ia-grp.com

Robert Motzer MD, board-certified medical oncologist of Memorial Sloan Kettering Cancer Center, discusses Progress In Advanced Kidney Cancer Treatment At ESMO Oncology Conference – Munich, Germany On October 19, 2018

Pascal Besman Chief Operating Officer at PharmaMar Discusses Differences Between NSCLC & SCLC. At ESMO Oncology Conference – Munich, Germany On October 19, 2018

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

Ricky Newton, CPA Director of Financial Services & Operations for Community Oncology Alliance describes the COAnalyzer Tool.

Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant Chief of Surgery Moffitt Cancer Center Professor of Urology, University of South Florida Discusses When Kidney Cancer Spreads Whats Next? At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant Chief of Surgery Moffitt Cancer Center Professor of Urology, University of South Florida Discusses Imaging Modalities In Kidney Cancer. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant Chief of Surgery Moffitt Cancer Center Professor of Urology, University of South Florida Discusses Challenges In Kidney Cancer. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center Discusses Integrative Medicine & Herbal Supplements. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center Discusses Immunotherapy Moving To Frontline. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Amishi Y. Shah, MD Assistant Professor Genitourinary Medical Oncology MD Anderson Cancer Center Discusses Gut Microbiome Upcoming Research. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.

Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, talks about the collective organizational efforts to improve stem cell transplant therapies for the treatment of hematological cancers through a trials acceleration model. Prof. Craddock outlines prospective trials, including a randomized donor leukocyte infusion (DLI) trial in patients who have undergone transplant, allogeneic/ autologous stem cell transplant trials, and trials looking into optimizing supportive patient care. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK. Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd

In this video, Dharmisha Chauhan, MPharm, of the Royal Marsden NHS Foundation Trust, London, UK, discusses the aims of her pharmacist and nurse-led clinic for patients with melanoma that are receiving immunotherapy. At the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Ms Chauhan highlights the importance for pharmacists to increase their skill set, in order to create a culture of advanced pharmacy practitioners in the future, and describes her experiences and roles that she plays within the clinic, to showcase the many opportunities for pharmacists.

Healthcare technologies and apps are important in supporting patients in their care, and can greatly benefit them in their treatment journey. Jonathan Moshinsky, from uMotif, London, UK, describes the advantages for both patients and healthcare professionals in using patient experience and symptoms trackers. Data collected from these activities can also act as useful resources in clinical research. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK. Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd

Kelly Baillie, of the NHS Greater Glasgow & Clyde, Glasgow, UK, presents the key findings from the Cancer Medicines Outcome Programme, a collaboration between NHS Greater Glasgow and Clyde and the University of Strathclyde with the aim of investigating whether medicines are as effective in real world populations, as they are in clinical trials. Looking specifically at men who received abiraterone and enzalutamide for the treatment of metastatic, castration-resistant prostate cancer, this initiative used electronic record linkage to combine the chemotherapy prescribing system with other useful patient information. At the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in…

At the 2018 British Oncology Pharmacy Association (BOPA) Annual Symposium, Simon Cheesman, MRPharmS, of University College London, London, UK, presented the experiences at University College Hospital London of making the switch to biosimilar rituximab for the treatment of selected patients receiving treatment for follicular lymphoma. One year on, we are joined by Mr Cheesman at the 2018 BOPA Annual Symposium in Birmingham, UK, to hear how this switch has impacted patients responses and treatment costs over the past 12 months. Content on www.vjoncology.com and www.vjhemonc.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd

From the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Simon Cheesman, MRPharmS, from University College London, London, UK, describes the key outcomes from the Phase III trial (NCT01696084) looking at CPX-351, a liposomal formulation of daunorubicin and cytarabine (DA), in a patient group aged between 60-75 years old. Compared with conventional DA chemotherapy, CPX-351 showed superior efficacy in terms of overall survival, with a comparable toxicity profile. Mr Cheeseman emphasizes the fact that dose administration is simpler and more convenient for both HCPs and patients. Content on www.vjoncology.com and www.vjhemonc.com from BOPA 2018 is supported…

Oncology Pharmacists play an important role in the treatment and management of patients, but how visible are they to their patients? When Oncology Pharmacist, Shereen Nabhani-Gebara, PharmD, BCOP, from Kingston University, London, UK, found herself on the other side of the table, it became clear to her that while patients and their carers receive an overwhelming amount of information regarding treatments, they have limited interaction with Oncology Pharmacists. Following this experience, Dr Nabhani-Gebara developed two surveys, one for parents of children receiving cancer treatment, and the other for Oncology Pharmacists, in order to learn more about this relationship. Content on…

Managing side effects can be an overwhelming experience for oncology patients, they may be unsure of the severity of their symptoms and could be reluctant to contact their healthcare team. Shereen Nabhani-Gebara, PharmD, BCOP, from Kingston University, London, UK, and her team have developed an app which aims to target this issue. Using this app, patients can look up their symptoms and receive useful information on how to management their symptom and, where necessary, are advised to seek medical attention. Dr Nabhani-Gebara tells us about the positive effect using this app has had on the breast cancer patients so far…

More than half of patients that undergo cancer treatment are estimated to have had at least one potential drug-drug interaction. Here, Jasmine Martin, MSc, of the University of Liverpool, Liverpool, UK, talks about the purpose of the Cancer Drug Interactions website as a tool to assist healthcare professionals in treating patients, while ensuring significant interactions are avoided. Speaking at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Ms Martin outlines the importance of smart apps in the healthcare setting. Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd

The increased use of targeted therapies in oncology has introduced a range of new side effects. Emma Foreman, BPharma (Hons) of The Royal Marsden NHS Foundation Trust, London, UK, discusses how these side effects, for example cardiological, neurological or rheumatoid side effects, have introduced the need for Oncology Pharmacists to become more knowledgeable on other specialities. Ms Foreman thinks that there is a role for groups like the British Oncology Pharmacy Association (BOPA) to produce training and educational materials to help Oncology Pharmacists bridge these knowledge gaps. This interview was recorded at BOPA Annual Symposium 2018, held in Birmingham, UK.…

A specialist workshop on non-medical prescribing was hosted at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, Birmingham, UK. The aim of this session was to encourage open discussion around the issues and challenges faced by Oncology Pharmacists. Emma Foreman, BPharma (Hons), from the Royal Marsden NHS Foundation Trust, London, UK, shares insights from the workshop which were of help to those new to non-medical prescribing. These included finding your area of expertise, what to consider when setting up a practise and working within a multidisciplinary team. Ms Foreman also highlights the importance of networking, especially through organisations like…

The British Oncology Pharmacy Association (BOPA) has a number of exciting educational initiatives in the pipeline for 2019. BOPA committee member, Bryn Thomas, MPharm, from The Royal Marsden NHS Foundation Trust, London, UK, tells us about the ongoing work at BOPA and their plans to organise for more networking events in the future to encourage engagement within the Oncology Pharmacist community. This video was recorded at the BOPA Annual Symposium 2018, held in Birmingham, UK. Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd

Advanced therapy medicinal products (ATMPs) are a novel class of medicines offering treatment options for diseases that currently lack effective therapies. Here, Anne Black, BPharm, of the Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, talks about three types of ATMPs, including gene therapy, somatic cell and tissue-engineered medicinal products. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK. Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd

Catherine Oakley, PhD, of Guy’s and St Thomas NHS Foundation Trust, London, UK, highlights the benefits of the nurse and pharmacy-led clinics currently being run at Guys Cancer Centre. Ms Oakley explains how the clinics are a great model for collaboration between oncology nurses and pharmacists, as nurses ensure patients receive better psychological and emotional support, while pharmacists ensure toxicity is closely managed. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK. Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd.

One of the topics discussed at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, was the question of what should a good, or even outstanding, clinical pharmacy service look like and how can this be achieved. Calum Polwart, MRPharmS, SPres, IPres, MSc, from the County Durham and Darlington NHS Foundation Trust, Darlington, UK, shares insights from this open discussion which saw the audience share their opinions and experiences. What resources and structures are needed in place to make these higher standards of practice achievable were addressed and, promisingly, by the end of this session 17…

Non-medical prescribing is one of the important tasks undertaken by Oncology Pharmacists. Bryn Thomas, MPharm, from The Royal Marsden NHS Foundation Trust, London, UK, shares insights from the non-medical prescribing workshop which took place during the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK. Mr Thomas discusses ways in which to ensure that non-prescribing is carried out efficiently and the role of the Pharmacist in its management. Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd

While artificial intelligence (AI) has revolutionized healthcare by minimizing the element of human error, thus improving efficiency, limitations do still exist. In this video, Bruce Burnett, MMedSci, of the University of Central Lancashire, Preston, UK, discusses the limitations of utilizing AI programs for prescription screening. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK. Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd

As chimeric antigen receptor (CAR) T-cell therapies are patient-specific, this novel treatment type poses unique challenges. From the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Anne Black, BPharm, of the Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, outlines the importance of the role pharmacists can play in ensuring governance and patient safety. Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd

Substitutable Medical Apps, Reusable Technologies (SMART) apps have been developed to meet the need for responsiveness in healthcare IT. In this video, Stefanie Krens, MSc, of Radboud University Medical Center, Radboud, Netherlands, talks about the Cancer Drug Interactions website and SMART app developed to minimize significant drug-drug interaction complications. This interview was recorded at the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK. Content on www.vjoncology.com from BOPA 2018 is supported by Napp Pharmaceuticals Ltd

Following the unfortunate IT failures at the Barts Health NHS Trust in 2017, which led to major issues in their electronic prescribing system, it became clear that it was necessary to review processes and devise a new, effective business continuity plan. Christopher Watson, MPharm, from St Bartholomews Hospital, London, UK, presents his experience in the development and rolling out of a new electronic prescribing system, highlighting key changes in practises which should help avoid future issues. Mr Watson hopes that through sharing his trust’s experiences, other centres can learn and will be encouraged to review their current prescribing systems. Content…

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Analyzing Biological Data From The Genome Atlas. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Kidney Cancer Histology Variables. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Rare Kidney Cancer Treatments. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Brian Shuch, MD Associate Professor of Urology at UCLA Discusses the Optimal Approach To Small Renal Mass. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.

Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Renal Medullary Carcinoma. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Pavlos Msaouel, MD, PhD Assistant Professor Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center discusses Immunotherapy In Chromophobe RCC. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.

Dr. Gerard Silvestri, Medical University of South Carolina, describes some of the typical presenting symptoms of lung cancer.

GRACE – Global Resource for Advancing Cancer Education Published on Feb 24, 2016 Dr. Gerard Silvestri, Medical University of South Carolina, discusses the benefits and drawbacks of lung cancer screenings.

VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY discusses Why Use Systemic Therapy Before Surgery?. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY discusses Radiotherapy In Kidney Cancer. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

VITALY MARGULIS MD ASSOCIATE PROFESSOR UROLOGIC ONCOLOGY discusses EA8143 PROSPER RCC: Adjuvant Therapy with a Twist. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Chung-Han Lee, MD/PhD Memorial Sloan Kettering Cancer Center Discusses Objective Response Rate, Best Indicator? At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Chung-Han Lee, MD/PhD Memorial Sloan Kettering Cancer Center Discusses Combinations in Kidney Cancer, Who Benefits? At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Chung-Han Lee, MD/PhD Memorial Sloan Kettering Cancer Center Discusses Combination, TKI, Immunotherapy Efficacy. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology Discusses Von Hippel-Lindau Disease. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Jose A. Karam, MD, FACS Associate Professor Departments of Urology and Translational Molecular Pathology Discusses Localized Recurrence Is Rare In An Isolated Fashion. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the current outlook of Waldenströms macroglobulinemia (WM), from hand-me-down to targeted approaches. The discovery of key growth and survival mutations, such as MYD88, has allowed the development of BTK inhibitors at the core of WM treatment. This video was recorded at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France.

Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, updates us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, on the results from the POLLUX trial (NCT02076009). Dr Usmani describes the overall median survival, median progression-free survival, and measurable residual disease data in early relapsed myeloma patients receiving daratumumab, lenalidomide and dexamethasone treatment.

Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, presents exciting results from clinical trials for bispecific antibodies targeting BCMA at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. Dr Usmani, explores the high efficacy and response rates observed in trials, where in a significant number of cases complete remission was also seen. As we expect more data on BCMA-targeting bispecfic antibody therapies at ASH 2018, Dr Usmani is excited at the prospects of this therapy in the relapsed/refractory setting.

Approved monoclonal antibodies for multiple myeloma (MM) are currently available, yet there are still gaps to explore in this therapeutic area for MM. At the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France, Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, discusses up-to-date clinical evidence for monoclonal antibody therapies, as well as the potential of bispecific antibodies and antibody-drug conjugates in MM.

What is the current treatment landscape for plasma cell leukemia and extramedullary disease in multiple myeloma (MM)? We spoke to Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, about this at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

The results of clinical trials are open to interpretation and are dependent upon a vast array of factors, including cohort size, the endpoints chosen and the statistics used to analyze the resulting date. Here, Robert Hills from the University of Oxford, Oxford, UK, discusses the most important considerations when judging the value of a clinical trial. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses the updated analysis of the CASTOR trial (NCT02136134) with us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France. This trial investigated daratumumab plus bortezomib/dexamethasone for relapsed/refractory multiple myeloma, and this follow-up showed excellent response rates and survival benefit, in addition to indicating the group that will receive the maximum benefit from this regimen.

Multiple myeloma (MM) therapy has evolved rapidly in recent years, and is showing no sign of slowing. Here, Kenneth Anderson, MD, from Harvard Medical School, Boston, MA, discusses interesting future treatment combinations from the European School of Haematology (ESH) International Conference on MM 2018. Dr Anderson highlights a number of approaches and devlopments, including the upcoming MMRF MyDRUG trial that will utilize genomic profiling and combination treatments.

Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Jesús San Miguel, MD, PhD, of the University of Navarra, Pamplona, Spain, discusses continuous and fixed duration therapy.

Heinz Ludwig, MD, PhD, from Wilhelminen Cancer Research Institute, Vienna, Austria, discusses treatment sequencing in multiple myeloma (MM). Dr Ludwig covers the many options available to treat MM, particularly when options are restricted in cases of drug resistance and relapse. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Evangelos Terpos, MD, PhD, of the University of Athens, Athens, Greece, discusses the evoling field of imaging in multiple myeloma, including PET/CT, full body MRI and diffusion weighted imaging. Dr Terpos also highlights the new standard of imaging for measurable residual disease.

Functional imaging techniques serve an essential role in diagnostics. Here, Elena Zamagni, MD, PhD, of the University of Bologna, Bologna, Italy, highlights the important applications of PET/CT in multiple myeloma (MM) management at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France. Dr Zamagni identifies the importance of PET/CT in MM mapping, prognosis, diagnose and management, while reflecting on the progress in standardizing the use of the technique in evaluating the response to therapy outside of the bone marrow.

Annemiek Broyl, MD, PhD, from Erasmus Medical Center and University, Rotterdam, Netherlands, discusses how to treat high-risk multiple myeloma (MM). Dr Broyl highlights trials such as MUK Nine (NCT03188172)., and emphasizes the importance of reaching for measurable residual disease negativity in this group of patients. This interview was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Alessandra Larocca, MD, PhD, of the University Hospital Città della Salute e della Scienza, Torino, Italy, discusses the importance of geriatric assessment in multiple myeloma (MM). In addition, Dr Larocca highlights the challenges related to elderly MM and what clinicians can do to manage these. This video was recorded at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France.

GRACE – Global Resource for Advancing Cancer Education Published on Feb 25, 2016 Dr. Gerard Silvestri, Medical University of South Carolina, describes several procedures used to obtain biopsy tissue in order to diagnose lung cancer.

Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.

Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Sequencing Immunotherapies In Kidney Cancer. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Ipilimumab & Nivolumab Combo. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses First Line Therapy In cMRCC. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Combo Avelumab & Axitinib. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Michael R. Harrison, MD Associate Professor of Medicine Duke University Medical Center Duke Cancer Institute discusses Combinations In Anti VEGF Kidney Cancer. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses VEGF Inhibitors In Adjuvant Kidney Cancer. At Kidney Cancer Association National Patient September 22, 2018.

Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses The Allure To The Immune Checkpoint Inhibitors. At Kidney Cancer Association National Patient September 22, 2018.

Naomi B Haas MD Director of Kidney and Prostate Cancer Clinical Programs Abramson Cancer Center discusses ASSURE, S-TRAC, ATLAS, & PROTECT Trials. At Kidney Cancer Association National Patient September 22, 2018

Susan Demo, Ph.D Calithera Biosciences discusses Only 3% Of Cancer Patients Participate In Clinical Trials at Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018

Mayer Fishman, MD PhD Dept. of GU Oncology Moffitt Cancer Center Dept. of Oncologic Sciences, USF Morsani College of Medicine discusses Kidney Cancer First Line Treatment at Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Susan Demo, Ph.D Calithera Biosciences Discusses the Best Way For A Patient To Find A Clinical Trial. At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Matt Campbell MD, MS Assistant Professor Department of Genitourinary Medical Oncology UT MD Anderson Cancer Center Discusses What Does PDL Positivity Mean On Biopsy? At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Matt Campbell MD, MS Assistant Professor Department of Genitourinary Medical Oncology UT MD Anderson Cancer Center Discusses When Should A Patient Receive Immunotherapy? At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

The utilization of interim positron emission tomography (PET) imaging to guide therapeutic decisions has the potential to further individualize therapy, avoid unnecessary treatment and associated toxicity, and optimize outcomes for patients with Hodgkin lymphoma (HL). In this activity, participants will learn about the different PET-adapted strategies being investigated in HL, with a focus on the interpretation of data for the practical use of interim PET, to help providers evaluate the current clinical evidence and applicability to their practice.

Philippe E. Spiess, M.D., MS, FRCS(C), FACS Senior Member, Department of GU Oncology Senior Member, Department of Tumor Biology Assistant Chief of Surgery Moffitt Cancer Center Professor of Urology, University of South Florida Discusses Where Does Kidney Cancer Spread? At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of New Jersey discusses What Is Cytoreductive Nephrectomy? At Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of New Jersey discusses the Role of Cytoreductive Nephrectomy in Metastatic RCC at Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of New Jersey discusses Cytoreductive Nephrectomy Viable Today at Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Eric A. Singer, MD, MA, FACS Assistant Professor of Surgery and Radiology Director, Kidney Cancer Program Rutgers Cancer Institute of New Jersey discusses Carmena Trial Results In Kidney Cancer at Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Brian Shuch, MD Associate Professor of Urology at UCLA Discusses the Risk Of New Tumor Developing at Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

Brian Shuch, MD Associate Professor of Urology at UCLA Discusses the Treatment Of The Incidental Renal Mass at Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health discusses Surgery in kidney cancer at Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health Discusses the Higher Risk Of Occurrence In Non-Metastatic RCC at Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL on September 22, 2018.

E Jason Abel, MD FACS University of Wisconsin School of Medicine and Public Health discusses the Complex Surgery Locally Advanced Kidney Cancer at Kidney Cancer Association National Patient and Caregiver Conference Chicago, IL September 22, 2018.

Steven Rosen, MD, from the City of Hope, Duarte, CA, discusses the remarkable quantity and quality of information on blood cancer therapeutics that has been collected and presented at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France. Dr Rosen expresses how it seems that we are very nearly approaching a cure for certain hematological malignancies, with the introduction of CAR T-cell therapy, bispecific antibodies and targeted therapies; all of which are producing promising results in clinical trials.

The field of blood cancer therapeutics has seen enormous progression. Here, Steven Rosen, MD, from the City of Hope, Duarte, CA, gives an overview of the exciting trials and research being conducted in the field of hematological malignancies at the City of Hope. The center is home to facilities where CAR T-cell and stem cell trials are underway, and targeted small molecules are being produced and trialed, eliminating the need for support from pharmaceutical companies. At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France, Dr Rosen reflects upon the success of the studies that have…

Speaking from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France, Bianca Santomasso, MD, PhD, of Memorial Sloan Kettering Cancer Center, NY, discusses how some of the nuances that pertain to systemic lymphoma also have implications for CNS lymphoma, such as the use of interferon-? to treat certain lymphoproliferative situations. Dr Santomasso comments on the interesting observations in patients with systemic lymphoma, in which there are patients who develop neurologic toxicity from therapies and those who have CNS metastasis.

Pablo Ortiz, MD, PhD, of the University Hospital 12 of October, Madrid, Spain, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, highlighting the current treatment in Spain for early-stage cutaneous T-cell lymphoma patients. Prof. Ortiz reflects on the importance of exposure to sun for mycosis fungoides patients.

Pablo Ortiz, MD, PhD, of the University Hospital 12 of October, Madrid, Spain, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, on the quality of life of patients with cutaneous T-cell lymphoma. Prof. Ortiz expresses his concerns about clinical outcomes and patient expectations as a doctor, and highlights the need to gather more information on patient-reported outcomes to support the decision-making process of doctors.

Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, discusses the future of checkpoint inhibitors in cutaneous lymphoma. He highlights the follow-up trial to CITN-10, CITN-13, which investigated pembrolizumab plus interferon-gamma 1b in relapsed/ refractory mycosis fungoides or Sézary syndrome (NCT03063632). He calls for the development of predictive markers of pembrolizumab response for cutaneous lymphoma, as well as research into synergist agents to improve response rates. This video was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland

Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland. Dr Khodadoust discusses the CITN-10 trial (NCT02243579), which investigated the use of pembrolizumab in relapsed/refractory mycosis fungoides or Sézary syndrome. He highlights the patient response rates and a uniquesideeffect that was observed in the Sézary population.

Topical alkylating agents have proven beneficial in treating patients with mycosis fungoides (MF). Here, Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, discusses this topic at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland. Prof. Baggot covers the access to chlormethine gel in France, and describes its potential in the treatment of early-stage MF as a stand-alone therapy, and in late-stage MF when used as an adjunct treatment.

Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, discusses the exciting new approval of the antibody mogumulizumab for cutaneous T-cell lymphoma. Speaking at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, she presents two case studies of patients who developed autoimmunity, where they entered complete remission for a significant period of time after receiving injections of this antibody. Prof. Bagot is excited about the therapy and accounts the antibodies successful response to its potential mechanism of regulatory T-cell depletion.

Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, on the progress of a new monoclonal antibody, IPH4102, being trialed for the first time in humans (NCT02593045). Prof. Bagot describes the results of the KIR3DL2-targeting antibody currently in Phase I of development, highlighting the plan to conduct the drug’s Phase II clinical trial in 2019 on patients of Sézary syndrome, mycosis fungoides and nodal peripheral T-cell lymphoma.

Maintenance therapy options for cutaneous T-cell lymphomas could be improved. Here, Rudolf Stadler, MD, PhD, of the University Medical Center Minden, Minden, Germany, discusses the RESMAIN study (NCT02953301), investigating resminostat as a maintenance therapy for advanced mycosis fungoides or Sézary syndrome. This video was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.

An accurate and optimized clinical scoring system is essential for the staging and management of cutaneous T-cell lymphoma. Here, Pietro Quaglino, MD, of the University of Turin, Turin, Italy, discusses his group’s retrospective study with a proposal for a scoring system for Sézary syndrome, in which particular features correlated with tumor burden and prognosis. This interview was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.

Establishing a registry and prognostic index for mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome, a rare type of CTCL, is important to improve the management of these conditions. In this interview, Julia Scarisbrick, MBChB, FRCP, MD, of the University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses the Prospective Cutaneous Lymphoma International Prognostic Indices (PROCLIPI), which is transforming this very area, and shares some of the results found. This video was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in…

CD47 has been found to be present on leukemic stem cells, but not on normal hematopoietic stem cells, offering an opportunity to target the source of the disease. Here, Irving Weissman, MD, of the Stanford University School of Medicine, Stanford, CA, discusses the use of an anti-CD47 antibody, which has shown promising results in combination with rituximab for follicular lymphoma and diffuse large B-cell lymphoma (NCT02953509). This interview was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.

Our understanding of stem cells has improved exponentially since their discovery, transforming our treatment of hematological malignancies and other diseases. Here, Irving Weissman, MD, of the Stanford University School of Medicine, Stanford, CA, discusses the use of stem cell transplantation and gives his perspective on their usage thus far. This interview was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.

A novel CD47-blocking checkpoint inhibitor has shown promising interim results in a multicenter Phase I trail for relapsed/refractory mycosis fungoides and S̩zary syndrome, the most common types of cutaneous T-cell lymphoma. Christiane Querfeld, MD, PhD, from City of Hope, Duarte, CA, discusses this agent Рthe fusion protein TTI-621 (SIRPaFc), which is injected intralesionally Рhere, and explores potential future avenues of study for this therapy. This interview was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland.

From the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting held in Nice, France, Francine Foss, MD, of Yale University School of Medicine, New Haven, CT, discusses the pathology and genetics of T-cell lymphoma with Jürgen Ruland, PhD, of Technical University of Munich, Munich, Germany. Prof. Foss and Prof. Ruland also expand on the nature of signalling pathways including TCR signalling and PD-1 expression in the disease, and how this impacts immunotherapies clinically investigated.

Precision medicine is improving outcomes, toxicity and disease management in trials and routine clinical practice. Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York City, NY, chaired a discussion at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting held in Nice, France, on how precision medicine is being used to improve lymphoma treatment. Dr Younes was joined by Thomas Witzig, MD, of Mayo Clinic, Rochester, MI, and Davide Rossi, MD, from the Institute of Oncology Research, Bellinzona, Switzerland. Topics covered included: current precision medicine clinical trials, using ctDNA to guide therapy, precision medicine across histologic subtypes,…

Cell-based therapies are an exciting area across the board in oncology. Here, our experts discuss the use of cellular therapy for viral lymphomas, in a discussion chaired by Catherine Bollard, MBChB, MD, FRACP, FRCPA, of the Children’s National Health System, Washington, DC. Joining the discussion are Ruth Jarrett, MD, PhD, from the University of Glasgow Center for Virus Research, Glasgow, UK, Mark Roschewski, MD, of the National Cancer Institute, Bethesda, MD, and Richard Little, MD, of the National Cancer Institute, Rockville, MD. The need for improved drug access in developing countries is highlighted by the experts, as well as the…

Viruses such Epstein-Barr virus (EBV) and HIV have been aetiologically linked to a significant number of lymphoproliferative diseases. In this roundtable discussion, lead by Catherine Bollard, MBChB, MD, FRACP, FRCPA, of the Children’s National Health System, Washington, DC, Dr Bollard covers the risk factors for viral lymphomas, as well as the current landscape for therapy and trial participation. She is joined by Ruth Jarrett, MD, PhD, from the University of Glasgow Center for Virus Research, Glasgow, UK, Mark Roschewski, MD, of the National Cancer Institute, Bethesda, MD, and Richard Little, MD, of the National Cancer Institute, Rockville, MD, at the…

While novel FLT3 inhibitors have been, or will be, approved for use as single agents in the treatment of acute myeloid leukemia (AML). Here, Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the increased efficacy of these drugs when combined with chemotherapy. Dr Perl states how newer generation FLT3 inhibitors in combination with chemotherapy may improve response rates and survival benefits in the frontline setting. He mentions that the future of FLT3 inhibitors as a combination therapy is continuously improving, which is exciting to witness. This interview was recorded at the 2018 Society of Hematologic Oncology (SOHO)…

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, describes how IDH inhibitors have significantly acute myeloid leukemia (AML) therapy. Dr Perl discusses how these treatments have increased survival rates in AML patients who have previously been unresponsive to therapy and those who were not candidates for intensive chemotherapy. He stresses the importance of personalized, precision medicines.

Venetoclax in combination with low intensity chemotherapy for acute myeloid leukemia (AML) in the frontline setting, which although currently under evaluation by the FDA, has shown impressive results. Speaking at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, is excited to share updates on the use of venetoclax as a frontline therapy for AML patients who are not candidates for intensive chemotherapy. Dr Perl, who is in support of the treatment, states that high risk patient groups, such as those with kidney impairment or the…

Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses clinical trials testing new drugs on patients with relapsed Hodgkin lymphoma. These agents include brentuximab vedotin and PD-1 blocking antibodies, which have been administered in combination and showed a high response rate of more than 80%, with a complete response rate of 62%. Prof. Ansell notes that these findings could possibly be better than some combination chemotherapy approaches used in the past. From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Prof. Ansell also highlights the importance of genetics as a useful prognostic factor; however, he stresses that…

With the the field of molecular diagnostics rapidly advancing, the demand for prognostic and diagnostic molecular information on myelodysplastic syndrome (MDS) is also increasing. Here, Torsten Haferlach, MD, PhD, of the Munich Leukaemia laboratory, Munich, Germany, speaks from the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, highlighting this issue. Prof. Haferlach uses examples of cases to stress the necessity for carrying out in-depth molecular background studies on patients with MDS using sequencing techniques such as next-generation sequencing (NGS), as opposed to the traditional chromosome banding method of diagnosis, to find the best treatment option for an MDS patient.…

Torsten Haferlach, MD, PhD, of the Munich Leukaemia laboratory, Munich, Germany, highlights the rapidly expanding field of molecular diagnostics, moving us towards personalized medicine for patients with myelodysplastic syndrome (MDS). Haferlach reflects on the success of existing demethylating drugs being used in MDS patients exhibiting the DNMT3A and TET2 gene mutations and explains the potential to uncover target approaches for further MDS-associated genes, specifically, splicing factor 3b subunit 1 (SF3B1) and tumor protein 53 (TP53) gene mutations. From 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Prof. Haferlach further discusses the future of MDS treatment, where the advancements in…

Knowledge of the molecular background of myelodysplastic syndrome (MDS) has been greatly advanced by developments in techniques such as next-generation sequencing (NGS) and ChIP-sequencing. Professor Torsten Haferlach, MD, PhD, of the Munich Leukaemia laboratory, Munich, Germany, highlights the discovery of several genes in MDS from his recent study using ChIP. Prof. Haferlachs findings bring significant prognostic, diagnostic and therapeutic value. From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Prof. Haferlach reports his finding of the splicing factor 3b subunit 1 (SF3B1) genetic mutation, paving way to a more specific diagnosis of MDS that so far was only…

The mechanism for the previously unknown occurrence of thrombocytopenia and neutropenia in patients with myeloma treated with immunomodulatory drugs (IMiDs) has finally been understood from clinical trials by Suzanne Lentzsch, MD, PhD, of Columbia University, New York City, NY. Dr Lentzsch explains that IMiDs such as revlimid and pomalidomide act by downregulating critical transcription factors, including IKZF1, pushing stem cells into one lineage and stopping maturation of progenitor cells and platelets. This mechanism provides a basis for hematopoietic malignancies as indicated by low white blood cell counts and platelets in patients taking IMiDs. This interview was recorded from the 2018…

Dr Suzanne Lentzsch, MD, PhD, of Columbia University, New York, NY, presents data from the latest clinical trials testing drugs for amyloidosis. Lentzsch reports on an ongoing study that compares the efficacy of CyBorD vs CyBorD combined with daratumumab, results of which could greatly influence treatment approaches for Amyloidosis in the near future. From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Dr Lentzsch emphasizes the need for more research on anti-amyloid antibodies, highlighting the recent success of FDA-approved drug tafamidis, which significantly increased overall survival in patients with amyloidosis.

From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses ways in which measuring measurable residual disease (MRD) may be useful. One way in which using MRD may be advantageous is when early intervention for a disease such as diffuse large B-cell lymphoma, is needed, and data is required to differentiate which patients are not cured and who are at risk of relapse. Prof. Ansell reports on findings from clinical trials using MRD to enable earlier intervention for lymphoma, and expresses hope for the future development of tools to…

Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses the dramatic and exciting approach of using CAR T-cells to treat patients with B-cell malignancies, particularly diffuse large B-cell lymphoma. From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Prof. Ansell reports on-going trials looking at other targets in Hodgkin Lymphoma, including CD30 and even the microenvironment of CD30, with a goal to work against macrophages that support growth of the malignant cell. Prof. Ansell also notes the challenges in developing treatments for T-cell lymphomas, such as targeting malignant cells and not non-malignant cells. A need for more…

From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Stephen Ansell, MD, PhD, of Mayo Clinic, Rochester, MN, discusses encouraging data on patients with Hodgkin lymphoma who received brentuximab vedotin who have shown complete response rates for more than five years now. These patients have not yet relapsed and are still off treatment, and Prof. Ansell suggests that these patients could potentially be cured. Prof. Ansell also stresses the need for more research into how long patients need brentuximab vedotin treatment for, as well as additional biological prognostic factors that can be targets for therapy. Despite genetic prognostic…

Pierluigi Porcu, MD, from the Sidney Kimmel Cancer Center, Philadelphia, PA, discusses recent clinical developments that have provided healthcare professionals with a clear landscape of the disease. Dr Porcu highlights how the creation of international registries, filled with an abundance of patient data sets, has enhanced the level of understanding of the disease. He also states that knowledge regarding the pathology and genetic profile of CTCL has significantly developed, hence the rise of precision medicine for the disease. He excitedly speaks about the success pre-clinical models of disease have had in practice. This was recorded at the 2018 Society of…

While mantle cell lymphoma (MCL) can be an aggressive disease, there is a subgroup of patients whose disease poses low risk, thus treatment may not be required. Here, Simon Rule, MD, from Plymouth University, Plymouth, UK, discusses this indolent patient group at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX. Prof. Rule explains the difficulties associated with defining this particular patient group, since there are no known baseline biological characteristics of indolent MCL. Prof. Rule also speaks about a large UK-based trial which aims to identify such baseline characteristics by closely monitoring newly diagnosed patients with…

With new targets identified over the past few years, the development of precision medicine has expanded significantly. Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu, MD, from, Sidney Kimmel Cancer Center, Philadelphia, PA, explores the many new drugs that are currently being trialed. Dr Porcu discusses monoclocnal antibody IPH4102, which has shown promising results in Phase I trials as well as oligonucleotide miR-155 and immunotherapies including pembrolizumab.

With cutaneous T-cell lymphoma (CTCL) being a rare disease with an incredibly high prevalence, Pierluigi Porcu, MD, from Sidney Kimmel Cancer Center, Philadelphia, PA, describes the challenges of CTCL at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX. Dr Porcu explains how treatment for CTCL patients is subject to the opinion of physicians, for example, dermatologists and medical oncologists may not agree in treatment choices. Dr Porcu also discusses the need for methods that can determine whether an individuals disease will progress or remain in the early stages.

At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Pierluigi Porcu from Sidney Kimmel Cancer Center, Philadelphia, PA, describes the MAVORIC trial (NCT01728805) investigating the efficacy of vorinostat with the novel monoclonal antibody mogamulizumab in patients with refractory or relapsed cutaneous T-cell lyphoma (CTCL). Dr Pierluigi shares the trial design and highlights that further research is needed in order to tackle the unmet needs of CTCL.

Despite benefits of targeted therapies for genetic mutations in AML, a limitation with this approach is that the mutation may only be present in a subset of cells or the mutation may not even be the driver of the disease. Dr Harry Erba of Duke University, Durham, NC, suggests that more general treatments such as chemotherapy or drugs inducing apoptosis in leukemia cells may be more effective. One such drug is Vadastuximab talirine, which targets the CD33 antibody, a cell surface molecule in AML. Dr Erba also discusses findings from clinical trials testing such antibody-based drugs in patients with AML.…

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham, NC, brings light upon the tendency of the healthcare community to favour an immediate diagnosis for patients with acute myeloid leukemia (AML), despite this doing more harm than good to patients. Waiting for genetic results can be a lengthy process, yet Dr Erba presents a compelling argument using evidence from a recent trial held in France in which patients with FLT3 mutations in AML showed increased chance of survival when taking targeted therapy. Dr Erba highlights the benefits of gene…

From the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Harry Erba of Duke University, Durham, NC, discusses the recently approved enasidenib and ivosidenib, which target IDH2 and IDH1 mutations in relapsed or refractory patients with acute myeloid leukemia (AML). Dr Erba outlines the outcomes of the CASCADE trial, and suggests that the use of an older, unfit sample and the administration of the highly immunosuppressive vadastuximab talirine with azacitidine may explain the outcome. Despite such challenges that may lead physicians to switch to chemotherapy instead, Dr Erba presents data to convince the healthcare community that gene-targeted…

From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer Center, Houston, TX, highlights the need to distinguish between high- and low-risk patients with essential thrombocythemia (ET). Prof. Verstovsek discusses management of ET, including the identification of differentiating prognostic factors that could inform physicians of the most effective treatment for patients. For instance, while ET patients at high-risk of thrombosis may benefit from cytoreductive therapy involving hydroxyurea and aspirin, low-risk patients do not need thi type of treatment, and may be prone to unnecessary risks. Prognostic assessment of patients have…

In this interview, Prof. Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer Center, Houston, TX, suggests that various parameters should be considered when monitoring patients before they progress to acute myeloid leukemia (AML), such as anemia and fibrosis. From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Prof. Verstovsek emphasises that genetic abnormalities can be detected in healthy people without the disease, so various other factors such as the bone marrow environment should be considered when making informed diagnostic and therapeutic decisions of myeloproliferative disorders.